
Celgene
VerifiedGlobal biopharmaceutical company committed to improving the lives of patients worldwide
Financials
EditEUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
---|---|---|---|---|---|---|---|
Revenues | - | 11.8b | 13.9b | - | - | - | - |
% growth | - | - | 18 % | - | - | - | - |
EBITDA | - | 5.4b | 5.6b | - | - | - | - |
% EBITDA margin | - | 46 % | 40 % | - | - | - | - |
Profit | - | 2.7b | 3.7b | - | - | - | - |
% profit margin | - | 23 % | 26 % | - | - | - | - |
R&D budget | 4.2b | 3.3b | 4.0b | - | - | - | - |
R&D % of revenue | - | 28 % | 29 % | - | - | - | - |
Source: Company fillings or news article
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - Not yet verified | |
N/A | N/A | IPO | |
* | $74.0b | Acquisition | |
Total Funding | - |
Recent News about Celgene
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Celgene
Edit
ACQUISITION by Eli Lilly May 2018

exited

ACQUISITION by Adaptive Biotechnologies Jan 2015

ACQUISITION by Celgene Jan 2018

exited

exited

exited

ACQUISITION by Ipsen Jun 2022

ACQUISITION by Celgene Dec 2009